Tarceva is a brand name of erlotinib, approved by the FDA in the following formulation(s):
TARCEVA (erlotinib hydrochloride - tablet; oral)
Manufacturer: OSI PHARMS
Approval date: November 18, 2004
Strength(s): EQ 100MG BASE, EQ 150MG BASE [RLD], EQ 25MG BASE
Has a generic version of Tarceva been approved?
No. There is currently no therapeutically equivalent version of Tarceva available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tarceva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Alkynyl and azido-substituted 4-anilinoquinazolines
Patent 5,747,498
Issued: May 5, 1998
Inventor(s): Schnur; Rodney Caughren & Arnold; Lee Daniel
Assignee(s): Pfizer Inc.
The invention relates to compounds of the formula ##STR1## and to pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.Patent expiration dates:
- November 8, 2018✓✓✓
- November 8, 2018
Stable polymorph on N-(3-ethynylphenyl)-6, 7-bis (2methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
Patent 6,900,221
Issued: May 31, 2005
Inventor(s): Norris; Timothy & Raggon; Jeffrey W. & Connell; Richard D. & Moyer; James D. & Morin; Michael J. & Kajiji; Shama M. & Foster; Barbara A. & Ferrante; Karen J. & Silberman; Sandra L.
Assignee(s): OSI Pharmaceuticals, Inc.
The present invention relates to a stable crystalline form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride designated the B polymorph, its production in essentially pure form, and its use. The invention also relates to the pharmaceutical compositions containing the stable polymorph B form of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine as hydrochloride, as well other forms of the compound, and to methods of treating hyperproliferative disorders, such as cancer, by administering the compound.Patent expiration dates:
- November 9, 2020✓✓✓
- November 9, 2020✓✓✓
- November 9, 2020✓✓✓
- November 9, 2020
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
Patent 7,087,613
Issued: August 8, 2006
Inventor(s): Norris; Timothy & Raggon; Jeffrey W. & Connell; Richard D. & Moyer; James D. & Morin; Michael J. & Kajiji; Shama M. & Foster; Barbara A. & Ferrante; Karen J. & Silberman; Sandra L.
Assignee(s): OSI Pharmaceuticals, Inc.
A method of monotherapy for a subject suffering from abnormal cell growth expressing the epidermal growth factor receptor (EGFR) which comprises orally administering to the subject a therapeutically effective amount of a crystalline polymorph of the hydrochloride salt of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine so as to treat the subject.Patent expiration dates:
- November 9, 2020✓
- November 9, 2020✓
- November 9, 2020
Alkynl and azido-substituted 4-anilinoquinazolines
Patent RE41065
Issued: December 29, 2009
Inventor(s): Schnur; Rodney Caughren & Arnold; Lee Daniel
Assignee(s): Pfizer, Inc.
OSI Pharmaceuticals, Inc.
The invention relates to compounds of the formula and to pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, n and m are as defined herein. The compounds of formula I are useful in the treatment of hyperproliferative diseases, such as cancer. The invention further relates to processes of making the compounds of formula I and to methods of using such compounds in the treatment of hyperproliferative diseases.Patent expiration dates:
- November 8, 2018✓✓
- November 8, 2018
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- September 19, 2011 - LABELING REVISIONS RELATED TO SMOKING AND ERLOTIMB EXPOSURE
- April 16, 2013 - MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES OF PLATINUM-BASED FIRST-LINE CHEMOTHERAPY
See also...
- Tarceva Consumer Information (Drugs.com)
- Tarceva Consumer Information (Wolters Kluwer)
- Tarceva Consumer Information (Cerner Multum)
- Tarceva Advanced Consumer Information (Micromedex)
- Tarceva AHFS DI Monographs (ASHP)
- Erlotinib Consumer Information (Wolters Kluwer)
- Erlotinib Consumer Information (Cerner Multum)
- Erlotinib Advanced Consumer Information (Micromedex)
- Erlotinib AHFS DI Monographs (ASHP)
No comments:
Post a Comment